Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › cholangiocarcinoma

Cholangiocarcinoma

Part of Intrahepatic Cholangiocarcinoma

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for cholangiocarcinoma

30 trials tracked for cholangiocarcinoma: 1 in phase 3 or 4.

30Trials tracked
1Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 1 Phase 2 22 Phase 1 3 Other / NA 4
  1. Phase 4 Etomidate vs. Midazolam for Sedation During ERCP Completed
  2. Phase 2 Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis Completed
  3. Phase 2 A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts Completed
  4. Phase 2 Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma Completed
  5. Phase 2 Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases Completed
  6. Phase 2 TAS-102 in Treating Advanced Biliary Tract Cancers Completed
Show 24 more trials
  1. Phase 2 A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Completed
  2. Phase 2 Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma Completed
  3. Phase 2 Study of Pembrolizumab and Olaparib in Bile Duct Cancer Completed
  4. Phase 2 M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) Completed
  5. Phase 2 A Study of TAS-120 in Patients With Advanced Solid Tumors Completed
  6. Phase 2 A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Completed
  7. Phase 2 Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma Completed
  8. Phase 2 Trial of IRE in Cholangiocarcinoma Completed
  9. Phase 2 Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) Completed
  10. Phase 2 A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma Completed
  11. Phase 2 A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) Completed
  12. Phase 2 Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations Completed
  13. Phase 2 Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma Completed
  14. Phase 2 Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) Completed
  15. Phase 2 Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery Completed
  16. Phase 2 A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma Completed
  17. Phase 2 Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers Completed
  18. Phase 1 A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer Completed
  19. Phase 1 The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma Completed
  20. Phase 1 A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors Completed
  21. N/A A Pilot Study to Assess Theragnostically Planned Liver Radiation to Optimize Radiation Therapy Completed
  22. N/A Personal Resilience Empowerment Program Study Completed
  23. N/A Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma Completed
  24. N/A Prospective Evaluation of Biliary Tissue Sampling With ERCP Completed

Showing the 30 most-cited and recently-updated of 30 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Migrated pancreaticojejunal stents may act as chronic local irritants potentially linked to metachronous cholangiocarcinoma
Oncology Sys. Review
Migrated pancreaticojejunal stents may act as chronic local irritants potentially linked to metachronous cholangiocarcinoma Migrated Surgical Stent Linked to Late Cancer Diagnosis
This case report describes a 62-year-old male with metachronous hilar cholangiocarcinoma and an intraoperatively migrated pancreaticojejunal…
A single case report suggests that an old, migrated surgical stent may act as a local irritant leading to cancer.
Frontiers Jun 23, 2026
Narrative review on KMT2C alterations in gastrointestinal cancers and therapeutic implications
Allergy & Immunology Sys. Review
Narrative review on KMT2C alterations in gastrointestinal cancers and therapeutic implications Genetic changes in gut cancers may open new treatment doors for patients
This narrative review synthesizes evidence on KMT2C alterations across gastrointestinal malignancies. It links KMT2C dysfunction to transcri…
A review of genetic changes in gastrointestinal cancers suggests new ways to treat tumors by targeting specific DNA repair weaknesses.
Frontiers May 28, 2026
Narrative review discusses cellular immunotherapy strategies for cholangiocarcinoma with noted limitations
Allergy & Immunology Sys. Review
Narrative review discusses cellular immunotherapy strategies for cholangiocarcinoma with noted limitations New CAR T Cell Strategy May Beat Tough Liver Cancer
This narrative review examines cellular immunotherapy approaches for cholangiocarcinoma, including CAR-based therapies, multi-antigen design…
A new plan to fight bile duct cancer combines advanced cell therapy with other drugs to break through tumor defenses.
Frontiers May 14, 2026

Research across Intrahepatic Cholangiocarcinoma

Related studies from across the Intrahepatic Cholangiocarcinoma family.

Systematic review and meta-analysis on neoadjuvant selection and liver transplantation for perihilar cholangiocarcinoma
Oncology Meta-analysis
Systematic review and meta-analysis on neoadjuvant selection and liver transplantation for perihilar cholangiocarcinoma Transplant selection may boost survival in bile duct cancer
This systematic review and meta-analysis synthesized evidence on protocol-based neoadjuvant selection and liver transplantation versus liver…
For a tough bile duct cancer, a new approach to choosing patients for transplant shows better long-term survival than surgery alone.
May 17, 2026
Lirafugratinib sequencing with futibatinib shows feasibility in FGFR2-driven cancers based on early-phase trial data
Oncology Phase I
Lirafugratinib sequencing with futibatinib shows feasibility in FGFR2-driven cancers based on early-phase trial data Can a new cancer drug work better if you switch to another drug after it stops?
This Phase I/II preprint trial evaluated lirafugratinib in 30 patients with FGFR2-driven cancers, including intrahepatic cholangiocarcinoma.
When a cancer drug stops working, switching to a different one might help because the two medicines attack the disease in slightly different…
Apr 16, 2026
Meta-analysis of GEO datasets identifies specific gene expression alterations in aflatoxin-associated intrahepatic cholangiocarcinoma
Genetics & Precision Medicine Meta-analysis
Meta-analysis of GEO datasets identifies specific gene expression alterations in aflatoxin-associated intrahepatic cholangiocarcinoma Could aflatoxin exposure change specific genes in liver cancer, and what does that mean for prevention?
This meta-analysis examined genomic data from five Gene Expression Omnibus datasets to identify expression patterns in aflatoxin-induced int…
Liver cancer linked to aflatoxin exposure changes six specific genes, revealing new genetic pathways that could help doctors find early warn…
Frontiers Apr 8, 2026